Efgartigimod alfa (Vyvgart) for Myasthenia Gravis

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2022年 / 64卷 / 1648期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：62 / 63
页数：2
相关论文
共 50 条
  • [21] ADAPT: A PHASE 3 STUDY OF FCRN ANTAGONIST, EFGARTIGIMOD, IN MYASTHENIA GRAVIS
    Howard, James
    Tuan Vu
    Bril, Vera
    De Bleecker, Jan
    Verschuuren, Jan
    Mantegazza, Renato
    Meisel, Andreas
    Peric, Stojan
    de Haard, Hans
    Parys, Wim
    Guglietta, Antonio
    Ulrichts, Peter
    Murai, Hiroyuki
    MUSCLE & NERVE, 2020, 62 : S76 - S76
  • [22] Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use (Mar, 10.1007/s40263-023-01000-z, 2023)
    Heo, Young-A
    CNS DRUGS, 2023, 37 (05) : 475 - 475
  • [23] Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
    Howard, James F., Jr.
    Bril, Vera
    Burns, Ted M.
    Mantegazza, Renato
    Bilinska, Malgorzata
    Szczudlik, Andrzej
    Beydoun, Said
    De Rivera Garrido, Francisco Javier Rodriguez
    Piehl, Fredrik
    Rottoli, Mariarosa
    Van Damme, Philip
    Tuan Vu
    Evoli, Amelia
    Freimer, Miriam
    Mozaffar, Tahseen
    Ward, E. Sally
    Dreier, Torsten
    Ulrichts, Peter
    Verschueren, Katrien
    Guglietta, Antonio
    de Haard, Hans
    Leupin, Nicolas
    Verschuuren, Jan J. G. M.
    Claeys, Kristl
    Diez-Tejedor, Exuperio
    Mathew, Veena
    Sgarzi, Manlio
    Harvey, Brittany Leigh
    Farias, Jerrica
    Frangiomore, Rita
    Heintzman, Sarah
    de Meel, Robert
    Chopra, Manisha
    Alboini, Paolo Emilio
    Hietala, Albert
    Genge, Angela
    NEUROLOGY, 2019, 92 (23) : E2661 - E2673
  • [24] A Real-life experience with Eculizumab and Efgartigimod in generalized Myasthenia Gravis patients
    Sacca, F.
    Cuomo, N.
    Russo, C.
    Campanile, M.
    Puorro, G.
    Marsili, A.
    Pane, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 569 - 569
  • [25] Assessing the extent of symptom control provided by ravulizumab or efgartigimod in generalised myasthenia gravis
    Kielhorn, Adrian
    Werneburg, Brian
    Hagenacker, Tim
    Meuth, Sven
    Scheiner, Christopher
    Masuda, Masayuki
    Powell, Lauren
    Jayasinghe, Pramoda
    Johnston, Karissa
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [26] A real world experience with Efgartigimod in generalized Myasthenia Gravis in a national reference center
    Antozzi, C.
    Frangiamore, R.
    Rinaldi, E.
    Vanoli, F.
    Andreetta, F.
    Ciusani, E.
    Bonanno, S.
    Maggi, L.
    Gallone, A.
    Pinna, A.
    Mantegazza, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 204 - 204
  • [27] A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients
    Pane, Chiara
    Di Stefano, Vincenzo
    Cuomo, Nunzia
    Sarnataro, Alessio
    Vinciguerra, Claudia
    Bevilacqua, Liliana
    Brighina, Filippo
    Rini, Nicasio
    Puorro, Giorgia
    Marsili, Angela
    Garibaldi, Matteo
    Fionda, Laura
    Sacca, Francesco
    JOURNAL OF NEUROLOGY, 2024, : 6209 - 6219
  • [28] The tale and trials of Efgartigimod: A newly FDA approved drug for the treatment of Myasthenia gravis
    Waqar, Kashaf
    Zainab, Anika
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2022, 72 (11) : 2366 - 2367
  • [29] EFGARTIGIMOD IN MYASTHENIA GRAVIS: UPDATE ON CLINICAL DEVELOPMENT AND PHASE 3 ADAPT STUDY
    Ulrichts, Peter
    Guglietta, Antonio
    Beauchamp, Jon
    de Haard, Hans
    Parys, Wim
    MUSCLE & NERVE, 2019, 60 : S133 - S133
  • [30] EFGARTIGIMOD IN MYASTHENIA GRAVIS: UPDATE ON CLINICAL DEVELOPMENT AND PHASE 3 ADAPT STUDY
    Ulrichts, P.
    Guglietta, A.
    Beauchamp, J.
    de Haard, H.
    Parys, W.
    MUSCLE & NERVE, 2019, 60 : S7 - S7
12345